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Aim: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction
are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of
mitochondrial KATP-channels by diazoxide is protective against doxorubicin cardiotoxicity, and if 5-hydroxydecanoate
(5-HD), a selective mitochondrial KATP-channel antagonist, abolished any protection by this intervention.
Methods: Wistar rats were divided into 7 groups (n = 6) and followed for 10 days with 5 intervention groups including
the following treatments: (1) Diazoxide and doxorubicin, (2) diazoxide and 5-hydroxydecanoate (5-HD), (3) 5-HD and
doxorubicin, (4) diazoxide and saline and (5) 5-HD and saline. On day 1, 3, 5 and 7 the animals received intraperitoneal
(i.p.) injections with 10 mg/kg diazoxide and/or 40 mg/kg 5-HD, 30 minutes before i.p. injections with 3.0 mg/kg
doxorubicin. One control group received only saline injections and the other control group received saline 30 minutes
prior to 3.0 mg/kg doxorubicin. On day 10 the hearts were excised and Langendorff-perfused. Cardiac function was
assessed by an intraventricular balloon and biochemical effects by release of hydrogen peroxide (H2O2) and troponin-T
(TnT) in effluate from the isolated hearts, and by myocardial content of doxorubicin.
Results: Doxorubicin treatment produced a significant loss in left ventricular developed pressure (LVDP) (p < 0.05) and
an increase in both H2O2 and TnT release in effluate (p < 0.05). Diazoxide significantly attenuated the decrease in LVDP
(p < 0.05) and abolished the increased release of H2O2 and TnT (p < 0.05). 5-HD abolished the effects of pretreatment
with diazoxide, and these effects were not associated with reduced myocardial accumulation of doxorubicin.
Conclusions: Pretreatment with diazoxide attenuates doxorubicin-induced cardiac dysfunction in the rat, measured by
physiological indices and TnT and H2O2 in effluate from isolated hearts. The effect could be mediated by opening of
mitochondrial KATP-channels, reduced doxorubicin-associated free radical generation and decreased cardiomyocyte
damage. Diazoxide represents a promising protective intervention against doxorubicin-induced acute cardiotoxicity.
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Doxorubicin is a widely used chemotherapy drug, but its
application is associated with cardiotoxicity. Free radical
generation and mitochondrial dysfunction are thought
to contribute to doxorubicin-induced cardiac failure [1,2].
Dose reduction protocols have been proposed to avoid the
risk of delayed cardiotoxicity, but this might be at the
expense of the anticancer effect [3]. In addition, im-
paired calcium handling and cellular damage mediated* Correspondence: lisa.drange.hole@helse-bergen.no
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unless otherwise stated.by reactive oxygen species, have been proposed as toxic
mechanisms to explain both acute and delayed cardio-
toxicity of anthracyclines [4-6].
Diazoxide has been in clinical use since the early
1960’s to treat severe non-malignant and malignant
hypertension in hospitalized adults and acute severe
hypertension in hospitalized children. Diazoxide is also
used to treat hypoglycaemia. The mechanisms of diazox-
ide’s clinical action relate predominantly to the opening
of pancreatic and smooth muscle KATP-channels [7].
Mitochondria are the major effectors of cardiopro-
tection by mechanisms that open the mitochondrial
KATP-channel, including ischemic and pharmacologicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hole et al. BMC Pharmacology and Toxicology 2014, 15:28 Page 2 of 8
http://www.biomedcentral.com/2050-6511/15/28preconditioning [8]. Pharmacological preconditioning,
mimicking ischemic preconditioning, is suggested as an
intervention to reduce doxorubicin cardiotoxicity [9].
Morphine has been demonstrated to mimic precondi-
tioning in cardiomyocytes [10,11]. We have previously
observed increased mortality in rats pretreated in vivo
with morphine before doxorubicin (32). In a follow-up
study we pretreated rats with morphine, isolated the
hearts and exposed them to doxorubicin in a Langendorff
perfusion system (unpublished data). We found that pre-
treatment with morphine in vivo was associated with a
cardiodepressive effect in isolated hearts before doxo-
rubicin exposure. After exposure to doxorubicin ex vivo,
isolated hearts from rats pretreated with morphine were
associated with increased release of hydrogen peroxide
(H2O2), increased release of troponin-T (TnT), increased
myocardial contracture and increased myocardial content
of doxorubicin. These findings were in contrary to results
from a comparable study [9] which found that morphine
was protective against doxorubicin cardiotoxicity. Based
on these opposing results we wanted to investigate fur-
ther, whether pharmacological preconditioning could re-
duce doxorubicin cardiotoxicity.
Direct stimulation of myocardial δ1-opioid receptors
leads to opening of mitochondrial KATP-channels and a
resultant increase in intracellular free radical signals
in vitro [10]. Recently, nicorandil, a mitochondrial KATP-
channel opener, has successfully been administered to
counteract the toxic effects of doxorubicin [12,13]. In
light of our previous results, we now wanted to bypass
the opioid receptors in this experiment, and study how
direct opening of mitochondrial KATP-channels interacts
with the cardiotoxic mechanisms of anthracyclines. We
used diazoxide, a selective mitochondrial KATP-channel
agonist, known to have protective properties against car-
diac ischemia [7,14]. We also used 5-hydroxydecanoate
(5-HD), a selective mitochondrial KATP-channel antag-
onist. 5-HD inhibits the increase in free radicals seen
with δ1-opioid receptor activation, and abolishes cardio-
protection afforded by ischemic preconditioning [7]. Our
model combines drug treatment in vivo with the study of
hearts ex vivo, yielding direct physiological information on
systolic and diastolic cardiac function combined with bio-
chemical indices like H2O2, TnTand measurement of myo-
cardial content of doxorubicin.
Methods
Materials
Doxorubicin was purchased from Meda AS (Slemmestad,
Norway), diazoxide, 5-hydroxydecanoate and pentobarbital
from Haukeland Hospital Pharmacy (Bergen, Norway),
heparin from Leo Pharma A/S (Oslo, Norway), and ingre-
dients for the Krebs-Henseleit bicarbonate buffer from
Merck KGaA (Darmstadt, Germany). This study conformsto the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996) and was approved by
the Animal Care and User Committee in Norway with
document number: ID 1766 FOTS, and certified institution
number 066 Vivarium, University of Bergen.
Animals
Male Wistar rats weighing 200 ± 20 grams were pur-
chased from Taconic (Ejby, Denmark). The animals were
housed in grid-bottom metal wire cages in a room main-
tained at a 12 hour light/dark cycle at a temperature of
20–22°C. They were acclimatised for two weeks, housed
three per cage and allowed free access to food pellets
(Pellets rodent, Special Diets Services, Essex, UK) and
tap water until i.p. injection of diazoxide, 5-HD, saline
or doxorubicin. The animals were separated in individual
cages based on their respective treatment protocols.
Langendorff perfusion model
The perfusion medium was a modified, oxygenated
(95% O2 and 5% CO2) Krebs-Henseleit bicarbonate buf-
fer (KHBB) (pH 7.4) containing in mM: 118.5 NaCl,
25.0 NaHCO3, 1.2 MgSO4, 4.7 KCl, 1.2 KH2PO4, 11.0
D-glucose, and 1.25 CaCl2. Hearts were excised after an-
aesthesia of the rats with an i.p. injection of pentobarbital
50 mg/kg (0.1 ml/100 g bodyweight) and heparinised i.p.
(0.1 ml 500 IU/100 g bodyweight). Anaesthesia was
evaluated by the pedal-withdrawal reflex. The heart was
rapidly excised and immediately placed in cold (4°C)
KHBB to temporarily stop its beating and preserve it
from ischemic injury prior to perfusion. The heart was
mounted on a steel cannula placed in the aorta and
perfused retrogradely in a Langendorff system with the
use of thermostated (37°C) reservoirs (Lauda, Lauda-
Königshofen, Germany), perfusion lines and heart cham-
ber. Pressure regulated flow was performed at 100 cmH2O
(73 mmHg), while volume regulated flow (12.5 ml/min)
was performed by use of an Alitea peristaltic pump (Alitea,
Stockholm, Sweden). A water-filled latex balloon was
placed in the left ventricle and connected to a pressure
transducer (Memscap AS, Skoppum, Norway) for the
recording of left ventricular pressure (LVDP) and second-
arily derived contractility indices. Left ventricular end-
diastolic pressure (LVEDP) was adjusted between 4 and
8 mmHg. A second pressure transducer was connected
to a side arm on the aortic cannula for the recording of
aortic pressure (AoP), an index of coronary vascular re-
sistance during volume-regulated perfusion. Pressure
signals were amplified (Quadbridge, AD Instruments,
London, UK) and recorded using a PowerLab data acquisi-
tion system (AD Instruments, East Sussex, UK). AoP, LVDP,
LVEDP, left ventricular pressure first derivatives maximum
(dp/dtmax) and minimum (dp/dtmin) were continuously
Figure 1 Drug treatment protocols.
Figure 2 Perfusion protocol.
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electric stimulation of 5 V amplitude of 3 ms duration)
was obtained by placing one electrode on the right aur-
icle and one on the steel cannula. Pacing was used to
maintain a standard contractile response to the experi-
mental drugs in the model not influenced by changes in
heart rate and/or periods of arrhythmia. Coronary flow
rate was measured by timed collection of the coronary
perfusate that dripped from the heart. At the end of
the perfusion protocol, hearts were removed from the
Langendorff system and myocardial tissue from the left
ventricle was dissected free and immediately frozen in
liquid helium and stored at −80°C until analysis of doxo-
rubicin and doxorubicinol was performed, within 14 days
of termination of the perfusion protocol. Effluent samples
of 1 mL were collected in 1.5 mL polypropylene Eppendorf
micro test tubes (Eppendorf Vertrieb, Wesseling-Berzdorf,
Germany) from each heart, at the end of the perfusion
protocol, and stored at 0°C, until analysis for TnT within
4 days of termination of the perfusion protocol. Effluent
samples of 1 mL were collected in Eppendorf tubes from
each heart at the end of the perfusion protocol, placed in a
thermostated (37°C) Eppendorf rack heated by a Lauda
reservoir (Lauda, Königshofen, Germany), and immediately
analysed for H2O2. All experiments and analysis were car-
ried out between 7 am and 7 pm.
Experimental design
DIADOX (n = 6) received pretreatment with an i.p.
injection of 10 mg/kg diazoxide 30 minutes before an i.p.
injection of 3 mg/kg doxorubicin.
DIA5HDDOX (n = 6) received pretreatment with an
i.p. injection of 10 mg/kg diazoxide 30 minutes before an
i.p. injection of 40 mg/kg 5-HD, 30 minutes before an i.p.
injection of 3 mg/kg doxorubicin.
5HDDOX (n = 6) received pretreatment with an i.p.
injection of 40 mg/kg 5-HD 30 minutes before an i.p.
injection of 3 mg/kg doxorubicin.
DIASAL (n = 6) received pretreatment with an i.p.
injection of 10 mg/kg diazoxide 30 minutes before an i.p.
injection of 0.9% saline.
5HDSAL (n = 6) received pretreatment with an i.p.
injection of 40 mg/kg 5-HD 30 minutes before an i.p.
injection of 0.9% saline.
SALSAL (n = 6) received pretreatment with an i.p.
injection of 0.9% saline 30 minutes before another i.p.
injection of 0.9% saline.
SALDOX (n = 6) received pretreatment with an i.p.
injection of 0.9% saline 30 minutes before an i.p.
injection of 3 mg/kg doxorubicin.
Injections were given on day 1, 3, 5 and 7 and proto-
cols are illustrated in Figure 1. On day 10 hearts wereexcised and Langedorff-perfused with the following proto-
col: 15 minutes stabilisation period with pressure-regulated
flow, followed by 5 minutes with pressure-regulated flow
and 5 minutes with volume-regulated flow. During the
latter 10 minutes physiological data were recorded, and
cardiac effluent samples collected for the evaluation of bio-
chemical and pharmacological parameters. The perfusion
protocol is illustrated in Figure 2.
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Doxorubicin and doxorubicinol were quantified by high
performance liquid chromatography (HPLC-MS/MS)
(1200 series RRLC, Agilent Technologies, USA) coupled to
an Agilent 6410 triple quadrupole mass spectrometer using
positive electrospray ionisation (Agilent Technologies,
USA). Frozen left ventricular tissue was minced and
weighted out in a glass tube with a screw cap and ho-
mogenized in physiological saline (2 ml/100 mg tissue)
with a tissue homogenizer (Ultra Turrax, Sigma Aldrich,
Germany). 1000 μl of sample was added 100 μl of dauno-
rubicin as internal standard (IS), and 200 μl of buffer
(1 M TRIZMA, pH 11.1) and mixed well before extrac-
tion with 4 ml ethylacetate/heptane (80/20 vol/vol). The
samples were mixed using a rotary blender for 15 minutes
and then centrifuged at 3500 rpm for 10 minutes at 10°C.
The organic phase was evaporated to dryness at 50°C
under nitrogen then dissolved in 100 μl of methanol
followed by 100 μl of distilled water. The extract was
mixed thoroughly and transferred to silanized vials before
analysis. 25 μl of extract was injected and separated on a
Zorbax SB-Aq (2.1 x 50 mm, 1.8 μm particles, Agilent
Technologies, USA) column using gradient elution with
acetonitrile and 0.1% formic acid in water. Quantifi-
cation was performed using multiple reaction monitoring
(MRM) mode at m/z 546.1→ 363.1 for doxorubicinol, m/z
544.1→ 361.1 for doxorubicin and m/z 528.1→ 321.1 for
daunorubicin (IS).
Effluent content of H2O2
H2O2 in cardiac effluent was measured using an Apollo
4000 electrochemical detection system (World Precision
Instruments, Sarasota, Florida, USA). The electrode was
calibrated using 9 serial dilutions of H2O2 in phosphate
buffered saline with added aniline. The current recorded
from the effluent was then calculated as μM H2O2.
Samples were kept at 37°C during measurement. The elec-
trode was allowed 3 minutes of stabilisation and 1 minute
of recording.
Effluent content of TnT
TnT in cardiac effluent was measured using an Elecsys
2010 immunoassay analyzer (Roche Diagnostics Norway
AS, Oslo, Norway), based on the sandwich principle.
Total duration of assay: 9 minutes. 1st incubation:
50 μL of sample, a biotinylated monoclonal cardiac TnT-
specific antibody, and a monoclonal cardiac TnT-specific
antibody labeled with a ruthenium complex (Tris(2,2-
bipyridyl)ruthenium(II)-complex (Ru(bpy))) reacted to
form a sandwich complex. 2nd incubation: After addition
of streptavidin-coated microparticles, the complex became
bound to the solid phase via interaction of biotin and
streptavidin. The reaction mixture was aspirated into the
measuring cell where the microparticles were magneticallycaptured onto the surface of the electrode. Unbound sub-
stances were then removed with ProCell. Application of a
voltage to the electrode then induced chemiluminescent
emission which was measured by a photomultiplier. Re-
sults were determined via a calibration curve which was
instrument-specifically generated by 2-point calibration
and a master curve (5-point calibration) provided via the
reagent barcode. Detection limit was 5.0 ng/L.
Statistics
All results are reported as mean values ± standard devi-
ation (SD) in tables. Groups were compared with regards
to parameters with a one-way analysis of variance
(ANOVA) and subsequently Fisher’s protected least-
significant difference test. SPSS for Windows version
17.0 was used and p < 0.05 was considered statistically
significant.
Results
All physiological results from the pressure regulated per-
fusion are presented in Table 1 and all physiological re-
sults from the volume regulated perfusion are presented
in Table 2. Biochemical results and doxorubicin analysis
are presented in Table 3.
During pressure regulated perfusion LVDP was signifi-
cantly (p < 0.05) higher in DIADOX (136.6 ± 2.9 mmHg)
compared to SALDOX (120.4 ± 3.6 mmHg) and LVEDP
was significantly (p < 0.05) lower in DIADOX (9.3 ±
1.5 mmHg) compared to SALDOX (15.4 ± 2.2 mmHg).
There was no significant difference in LVDP, LVEDP or
coronary flow in DIA5HDDOX or 5HDDOX versus
SALDOX.
During volume regulated perfusion LVDP was signifi-
cantly (p < 0.05) higher in DIADOX (141.5 ± 6.9 mmHg)
compared to SALDOX (117.1 ± 9.1 mmHg). LVEDP
was significantly (p < 0.05) lower in DIADOX (9.6 ±
2.5 mmHg) compared to SALDOX (18.0 ± 13.2 mmHg).
AoP was significantly (p < 0.05) lower in DIADOX
(103.9 ± 2.2 mmHg) compared to SALDOX (133.7 ±
5.0 mmHg). dp/dtmax was significantly (p < 0.05) higher in
DIADOX (3697.4 ± 141.0 mmHg/s) compared to SALDOX
(2777.8 ± 386.9 mmHg/s). dp/dtmin was not significantly
different in DIADOX versus SALDOX, and there was no
significant difference in LVDP, LVEDP, AoP, dp/dtmax or
dp/dtmin in DIA5HDDOX or 5HDDOX versus SALDOX.
There was no significant difference in dp/dtmax or dp/dtmin
between any of the groups during pressure regulated
perfusion.
Coronary flow was significantly higher (p < 0.05) in
DIADOX (11.3 ± 1.8 ml/min) compared to SALDOX
(8.9 ± 1.7 ml/min) during pressure regulated perfusion.
There was no significant difference in coronary flow dur-
ing pressure regulated perfusion in DIA5HDDOX or
5HDDOX versus SALDOX.
Table 1 Physiological results from pressure regulated perfusion
DIADOX DIA5HDDOX 5HDDOX DIASAL 5HDSAL SALSAL SALDOX
LVDP (mmHg) 136.6 ± 2.9* 122.9 ± 4.4 117.5 ± 5.2 146.4 ± 6.8* 144.6 ± 5.1* 152.7 ± 11.0* 120.4 ± 3.6
LVEDP (mmHg) 9.3 ± 1.5* 16.1 ± 1.8 14.9 ± 2.7 8.2 ± 1.5* 8.1 ± 1.6* 8.3. ± 1.6* 15.4 ± 2.2
AoP (mmHg) 73.0 ± 0 73.0 ± 0 73.0 ± 0 73.0 ± 0 73.0 ± 0 73.0 ± 0 73.0 ± 0
Heart rate (beats per minute) 300 ± 0 300 ± 0 300 ± 0 300 ± 0 300 ± 0 300 ± 0 300 ± 0
dp/dtmax (mmHg/s) 3525.5 ± 949.9 3295.3 ± 895.9 3283.4 ± 621.9 3647.4 ± 563.7 3522.5 ± 120.1 4499.1 ± 887.2 3026.6 ± 150.0
dp/dtmin (mmHg/s) −2176.5 ± 1147.9 −2012.3 ± 282.3 −1952.7 ± 373.9 −2921.9 ± 200.3 −3050.9 ± 277.6 −3060.1 ± 311.3 −2173.0 ± 195.1
Coronary flow (ml/min) 11.3 ± 1.8* 9.5 ± 0.7 8.8 ± 1.2 11.8 ± 1.2* 12.0 ± 1.3* 12.6 ± 0.4* 8.9 ± 1.7
Values presented as mean ± standard deviation (SD). *Significantly different from hearts in SALDOX, p < 0.05.
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doxorubicinol accumulation in myocard in any of the
intervention groups versus SALDOX. TnT was signifi-
cantly (p < 0.05) lower in DIADOX (67.3 ± 7.9 ng/L)
compared to SALDOX (121.0 ± 17.2 ng/L). H2O2 con-
centration in effluate was significantly (p < 0.05) lower in
DIADOX (54.9 ± 2.6 μM) compared to SALDOX (73.5 ±
2.4 μM). There was no significant difference in TnT or
H2O2 in DIA5HDDOX or 5HDDOX versus SALDOX.
Discussion
Pretreatment with diazoxide attenuated doxorubicin-
induced cardiac dysfunction in the rat in the present
study. Doxorubicin treatment produced a significant loss
in left ventricular developed pressure (LVDP) (p < 0.05)
both in volume- and pressure regulated perfusion similar
to previous reports [15,16]. Diazoxide significantly atten-
uated this decrease in LVDP (p < 0.05) in both perfusion
protocols. Diazoxide also improved diastolic dysfunction
in doxorubicin treated hearts, by lowering the elevation
of LVEDP (p < 0.05) in both perfusion protocols, com-
pared to animals that received both diazoxide and 5-HD.
The protective effect of diazoxide is equivalent to that of
ischemic preconditioning, and diazoxide is often used as
a pharmacological means to induce preconditioning [7].
The drug has previously been described as an agent with
a unique molecular target by opening of mitochon-
drial KATP-channels in cardioprotection. However, moreTable 2 Physiological results from volume regulated perfusio
DIADOX DIA5HDDOX 5HDDOX
LVDP (mmHg) 141.5 ± 6.9* 127.9 ± 4.3 108.1 ± 9.
LVEDP (mmHg) 9.6 ± 2.5* 16.0 ± 2.2 15.8 ± 2.1
AoP (mmHg) 103.9 ± 2.2* 124.2 ± 5.1 130.5 ± 7.
Heart rate (beats per minute) 300 ± 0 300 ± 0 300 ± 0
dp/dtmax (mmHg/s) 3697.4 ± 141.0* 2512.9 ± 302.0 2950.7 ± 23
dp/dtmin (mmHg/s) −2380.6 ± 157.0 −2176.4 ± 154.8 −2530.1 ± 25
Coronary flow (ml/min) 12.5 ± 0 12.5 ± 0 12.5 ± 0
Values presented as mean ± standard deviation (SD). *Significantly different from herecently a consensus seems to emerge that there are nu-
merous effectors involved in the cardioprotective effects of
diazoxide, and these effectors may synergistically contrib-
ute to its cardioprotective properties [7].
With volume regulated flow, the effects on doxorubicin-
induced coronary vascular resistance, can be studied in
parallel with effects on myocardial contractility. During
volume regulated perfusion, aortic pressure, an indirect
measure of coronary resistance, was increased in hearts
that received both diazoxide and 5-HD, or just 5-HD, be-
fore doxorubicin. However, diazoxide pretreatment attenu-
ated this effect. The vasodilatory effects of diazoxide in
vascular smooth muscle are due to opening of vascular
KATP-channels. KATP-channels have a pronounced role in
controlling coronary blood flow and the coronary reserve,
particularly in the resistance arterioles [17]. In some studies
diazoxide has been noted to improve coronary flow, which
is associated with cardioprotection, in perfused hearts [18],
despite the fact that the coronary flow reserve is low in
crystalloid-perfused hearts [19]. Coronary flow was sig-
nificantly higher (p < 0.05) in DIADOX compared to
SALDOX during pressure regulated perfusion. This ef-
fect was abolished with 5-HD. Based on these results,
improved cardiac function associated with preserved cor-
onary flow during pressure regulated perfusion, and atten-
uated increase in aortic pressure during volume regulated
perfusion, could account for some of the cardioprotective
effects of diazoxide.n
DIASAL 5HDSAL SALSAL SALDOX
3 149.5 ± 10.8* 155.6 ± 13.0* 162.9 ± 14.7* 117.1 ± 9.1
10.6 ± 1.8* 8.2 ± 1.0* 9.3 ± 1.6* 18.0 ± 13.2
3 82.7 ± 6.0* 76.0 ± 3.5* 76.9 ± 3.6* 133.7 ± 5.0
300 ± 0 300 ± 0 300 ± 0 300 ± 0
7.5 4583.6 ± 546.9* 3935.7 ± 213.6* 3973.6 ± 246.9* 2777.8 ± 386.9
1.4 −2940.8 ± 261.6 −3041.6 ± 403.1 2862.0 ± 295.1 −2579.8 ± 329.1
12.5 ± 0 12.5 ± 0 12.5 ± 0 12.5 ± 0
arts in SALDOX, p < 0.05.
Table 3 Biochemical results and drug analysis
DIADOX DIA5HDDOX 5HDDOX DIASAL 5HDSAL SALSAL SALDOX
Troponin -T effluate concentration ng/L 67.3 ± 7.9* 126.3 ± 20.5 130.0 ± 16.9 27.0 ± 4.9* 26.8 ± 4.9* 28.0 ± 5.3* 121.0 ± 17.2
H2O2 effluate concentration (μM) 54.9 ± 2.6* 72.8 ± 9.2 70.6 ± 5.7 24.8 ± 3.0* 26.1 ± 2.5* 22.8 ± 1.7* 73.5 ± 2.4
Doxorubicin tissue concentration nmol/g 1.9 ± 0.3 2.7 ± 0.4 3.3 ± 1.8 0 ± 0 0 ± 0 0 ± 0 2.6 ± 0.5
Doxorubicinol tissue concentration nmol/g 0.4 ± 0 0.7 ± 0.3 0.4 ± 0.1 0 ± 0 0 ± 0 0 ± 0 0.5 ± 0.2
Values presented as mean ± standard deviation (SD). *Significantly different from hearts in SALDOX, p < 0.05.
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of H2O2 in cardiac effluate compared to hearts that were
pretreated with 5-HD and diazoxide or 5-HD alone.
Diazoxide is an inhibitor of the mitochondrial complex
II protein, succinate dehydrogenase (SDH). This inhib-
ition also occurs in the heart [20]. The activity of SDH is
a site of reactive oxygen species (ROS) generation, and
the possibility has been raised that diazoxide and other
SDH inhibitors mediate some of their cardioprotective
effects via modulation of ROS production. Which ROS
signals cardioprotection is mediated through is not fully
understood [8]. Opening of mitochondrial KATP-chan-
nels leads to increased ROS, leading to a persistent open
state of the channel. The ROS responsible for this is not
known [7]. H2O2 has been proposed as one candidate
for this effect, although one study concludes that H2O2
is not the mediator of mitochondrial KATP-channel-
dependent ROS signalling [8]. In our study we found
higher levels of H2O2 in effluate from hearts that had
not undergone diazoxide pretreatment before doxorubi-
cin, or that had received both 5-HD and diazoxide
before doxorubicin. The level of H2O2 associated with
cellular signalling is much lower than the levels associ-
ated with cardiotoxicity [21]. The present study was not
designed to examine signalling effects, and our observa-
tions are thus associated with the reduced cardiotoxicity
of doxorubicin. This is supported by our observation of
diazoxide improving diastolic dysfunction in doxorubicin
treated hearts, by lowering the elevation of LVEDP. Dia-
stolic dysfunction and contracture is proposed to be re-
lated to ROS generation [22,23].
Diazoxide pretreated hearts also had lower concentra-
tions of TnT in cardiac effluate compared to hearts that
were pretreated with 5-HD and diazoxide or 5-HD
alone. Troponins are myocardial regulatory proteins,
which regulate the calcium mediated actin and myosin
interaction. Troponin-T is widely used as a specific
marker to diagnose myocardial infarction. Doxorubicin
is associated with increased TnT in serum and in heart
effluate [15,24,25].
Finally, pretreatment with diazoxide was not associated
with decreased myocardial accumulation of doxorubicin or
doxorubicinol which suggest that the protective effects did
not involve a change of distribution of the anthracycline to
the heart in vivo.Limitations
In this study we wanted to investigate if opening of
mitochondrial KATP-channels by diazoxide is protective
against doxorubicin cardiotoxicity. Mitochondrial KATP-
channels have been implicated as important mediators
of preconditioning [26,27]. However, the evidence for their
role in preconditioning is primarily based on the effects of
pharmacological agents, in particular, diazoxide and 5-HD.
Diazoxide has been reported to be a specific opener of
mitochondrial KATP channels, but studies have suggested
that its mechanism of cardioprotection may be due to
other actions, such as inhibition of succinate dehydrogen-
ase [28,29], activation of sarcolemmal KATP channels [30]
or transient opening of the mitochondrial permeability
transition pore [31]. In addition, it might be argued that
the complex metabolic effects of 5-HD severely limit its
usefulness as a ‘selective’ blocker of mitochondrial KATP
channels [32]. Furthermore, since their identification heav-
ily relies on the use of diazoxide as a specific opener and
5-HD as a specific blocker, the very existence of mitochon-
drial KATP channels may be questioned. This skeptical view
is supported by a study in which no changes in mitochon-
drial matrix volume induced by diazoxide or 5-HD could
be detected [33]. Hence, one view on 5-HD is that it
should no longer be considered a useful tool for studying
the role of mitochondrial KATP channels in preconditioning
[32]. Thus, although diazoxide attenuated doxorubicin-
induced cardiac dysfunction in our results, our model was
not designed to establish the precise protective mecha-
nisms. Furthermore, we cannot exclude that the protective
effects involved a change in distribution of doxorubicin to
different compartments within the heart.
Conclusion
The main observation in the present results is that pre-
treatment with diazoxide attenuates doxorubicin-induced
cardiac contractile dysfunction, and attenuates release of
biomarkers of cardiotoxicity in effluate without decreas-
ing the accumulation of doxorubicin. 5-HD completely
abolished this effect of diazoxide in our rat model. A pos-
sible mechanism could be opening of mitochondrial
KATP-channels. However, we cannot exclude other effects
of the drug, including opening of vascular KATP-channels.
The low specificity of 5-HD, calls for additional studies of
mechanisms of a promising protective intervention.
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